Pathways of Care and Early Psychosis: Survey DSM ASL BARI
Poster C118, Saturday, October 22, 11:30 am - 1:00 pm, Le Baron
Pietro Nigro1, Domenico Semisa2, Paola Clemente1, Giovanni Carrieri1, Brunella Camillo1, Valeria Latorre1, Rossana Linsalata3, Gaetano Nappi1, Apostolos Papazacharias1, Maria Grazia Porcelli3; 1Mental Health Department ASL BARI - Psychiatrist, 2Mental Health Department ASL BARi - Director of Department of Mental Health – ASL BA, 3Mental Health Department ASL BAR - Psychologist
Purpose Over the past two decades, several Meta-analyzes have shown the effectiveness of cbt in psychosis (CBTp), on the positive, negative symptoms, depressive and psychosocial functioning (Gould et al., 2001; Rector and Beck, 2001; Zimmermann et al., 2005; Wykes et al., 2008; Sarin et al., 2011). The use of CBTp is recommended at different stages of treatment: the ultra-high-risk subjects (UHR), in the beginning, in the maintenance and compared with resistant symptoms (DGPPN, 2006; NICE, 2014, PORT, 2009). In particular, in UHR subjects, the NICE guidelines propose as an elective treatment cbt (NICE, 2013). Recently, the State-Regions Conference, in Italy, approved the document on PDTA for schizophrenic disorders (2014). The pathways of care (PDTA) are, together with Guidelines, tools that allow you to verify the suitability of assistance delivered. The PDTA aim to contextualize the recommendations of the Guidelines, within a specific organizational reality. Materials and Methods The purpose of the research is to assess the degree of "enforceability" of proposed recommendations in PDTA on schizophrenic disorders in the operational reality of the DSM ASL Ba. A questionnaire to 25 items drawn from the PDTA recommendations for schizophrenic disorders (2014), will be administered to the DSM ASL Bari operators, in order to obtain opinions to define pathways to care in the beginning of psychosis in DSM ASL Bari, with particular reference to applicability of psychosocial interventions. Results: data processing is in progress and will be available by the end of May 2016.
Topic Area: Ultra High Risk / Prodromal Research